The objective is to maintain a globally leading role in space by safeguarding and further developing a cost-effective, competitive and innovative space industry (including SMEs) and research community and by fostering space-based innovation.

The objective is to maintain a globally leading role in space by safeguarding and developing a competitive space industry and research community and by fostering space-based innovation.

Calls for EU quality and security standards, as well as an EU system and network of laboratories for the certification of CBRN security equipment and technologies, to be developed; underlines that strict security standards and hiring procedures also need to apply to personnel employed at facilities with access to harmful agents; calls for the sharing and use of best knowledge and expertise from both the civil and military fields; again under the leadership of the Commission, stresses that the necessary research and development funding should be provided to ensure that applied research and major demonstration programmes with an EU dimension are carried out, and, given the fragmentation of this market, that an EU industrial policy in the f ...[+++]ield of civil security is needed, stimulating cooperation between enterprises in the EU and with specific support for small and medium-sized enterprises/small and medium-sized industries (SMEs/SMIs), which create a significant share of innovation under the FP7/Security, which should be increased, and that efforts should be made to stimulate cooperation (particularly cross-border cooperation) between European enterprises; wishes to see the emergence of a comprehensive project management capability to manage all aspects of CBRN security projects, covering the entire life cycle of the CBRN threat (prevention, detection and response); calls on the Commission to propose a strategy for developing the biodefence industry in Europe;

As a result of the high cost of research and development, the pharmaceuticals industry is reluctant to develop medicinal products intended for the treatment of rare conditions, as well as those called 'orphan medicinal products', for which the market is smaller.

The Commission has also gained sufficient experience in the application of Articles 87 and 88 of the Treaty in the fields of training aid, employment aid, environmental aid, research and development and innovation aid and regional aid with respect to both SMEs and large enterprises, in particular in the context of the implementation of Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid , Commission Regulation (EC) No 2204/2002 of 12 December 2002 on the application of Articles 87 and 88 of the EC Treaty to State aid for employment , Commission Regulation (EC) No 1628/2006 of 24 October 2006 on the application of Articles 87 and 88 of the Treaty to national regio ...[+++]nal investment aid the Community framework for State aid for research and development , the Community Framework for State aid for research and development and innovation, the 2001 Community guidelines on State for environmental protection , the 2008 Community guidelines on State aid for environmental protection and the Guidelines on national regional aid for 2007-2013

As a result of the high cost of research and development, the pharmaceuticals industry is reluctant to develop medicinal products intended for the treatment of rare conditions, as well as those called 'orphan medicinal products', for which the market is smaller.